CD274 and cancer: According to the latest research results released at the annual meeting of the Cancer Immunotherapy Society, PD-L1 targeted drugs combined with multi-kinase inhibitors with anti-angiogenic activity have produced clinical responses in TLS-positive tumor patients, even in cancer types that are usually considered resistant to checkpoint inhibitors [99].